EP0029581B1 - Amino substituted tetrahydrobenzindoles, a process for preparing and a pharmaceutical composition containing the same - Google Patents
Amino substituted tetrahydrobenzindoles, a process for preparing and a pharmaceutical composition containing the same Download PDFInfo
- Publication number
- EP0029581B1 EP0029581B1 EP80107188A EP80107188A EP0029581B1 EP 0029581 B1 EP0029581 B1 EP 0029581B1 EP 80107188 A EP80107188 A EP 80107188A EP 80107188 A EP80107188 A EP 80107188A EP 0029581 B1 EP0029581 B1 EP 0029581B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- tetrahydrobenzindoles
- halogen
- preparing
- sup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 0 *CNC(C1)Cc2ccc(*)c3c2c1c(*)[n]3* Chemical compound *CNC(C1)Cc2ccc(*)c3c2c1c(*)[n]3* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention is concerned with certain aminosubstituted tetrahydrobenzindoles, their preparation and pharmaceutical use.
- the compounds have pharmacological activity, e.g. antihypertensive, prolactin inhibition, anti-Parkinson agent.
- alkyl of 1 to 3 carbon atoms methyl, isopropyl and ethyl are preferred.
- the monosubstituted phenyl groups are chlorophenyl, iodophenyl, methoxyphenyl isopropoxyphenyl and n-propylphenyl.
- Examples of the (mono)substituted phenyl-C l -C 3 -alkyl group are benzyl, bromophenyl-C 3 H 6 ⁇ , ethoxyphenyl-C 2 H 4 ⁇ and methylphenyl-CH 2 ⁇ .
- the preferred monosubstituted phenyl group is the same as that defined above.
- the term halogen includes Br, Cl, F and iodo with Br, CI and F being preferred and Br and CI being more preferred.
- An example for R 3 is OCH 3 .
- the pharmaceutically acceptable salts are the salts of Formula I with suitable inorganic or organic acids.
- suitable organic acids are carboxylic acids such as acetic acid, fumaric acid, maleic acid, succinic acid, pamoic acid, pivalic acid and oxalic acid and non carboxylic acid such as isethionic acid and naphthalene disulfonic acid.
- useful inorganic acids are the hydrohalides such as HCI and HBr, H 2 SO 4 and phosphoric acid.
- C l -C 3 alkyl is preferably methyl and R 2 is H.
- R is CH 3 and R', R 2 and R 3 are all H.
- Another class of preferred compounds has the formula III
- R 2 is H.
- R is phenyl and R', R 2 and R 3 are all H.
- the compounds of the present invention are active antihypertensives.
- a representative compound was tested in a protocol using a spontaneously hypertensive (SH) rat model to demonstrate this activity. This test indicates that the present compounds would be useful in treating hypertension in hypertensive human patients.
- SH spontaneously hypertensive
- the compounds of the present invention are administered to the hypertensive patient by any convenient mode of administration e.g. orally or parenterally using appropriate dosage e.g. tablets, emulsions, solutions, capsules for oral administration and solutions, suspensions, emulsions for parenteral administration.
- appropriate dosage e.g. tablets, emulsions, solutions, capsules for oral administration and solutions, suspensions, emulsions for parenteral administration.
- Conventional procedures are used to prepare suitable pharmaceutical compositions in proper dosage forms using conventional, pharmaceutically acceptable diluents, compounding ingredients, and the like.
- Sufficient amount of a compound of the present invention is administered to the patient to produce the desired therapeutic effect i.e. lowering of high blood pressure.
- Suitable dosages will thus vary and the daily dosage in humans may range from about 10 mg. to about 3000 mg., preferably about 20 mg. to about 1000 mg. and more preferably about 50 mg. to about 500mg.
- the present compounds also have other pharmacological properties which make them useful in humans as prolactin inhibitors or for treating Parkinson's disease, at appropriate dosages and using appropriate modes of administration e.g. parenterally or orally.
- the compounds of the present invention may be prepared by any available process.
- a convenient process useful for this preparation is illustrated by the following set of equations: the term “tos” stands for the tosylate or p-tolylsulphonyl moiety.
- the compound A is known [see Bowman et al., J. C. S. Perkin I, 438 (1973)].
- Treatment of A with 1 suitable anhydride or acyl halide introduces the substituent on the amino N (compound B).
- the ketone group adjacent to the amino group is then thioketalized by treatment with 1,3-propanedithiol and trimethylsilylchloride in chloroform using conventional conditions to yield the C product.
- the thioketal group is removed by treatment with a suitable catalyst such as Raney nickel to yield compound D.
- the product (D) obtained is then hydrogenated using an appropriate system such as lithium aluminum hydride to yield the desired final product E.
- Step A 4-Acetamino-1,3,4,5-tetrahydro-1-(p-tolylsulphonyl)benz[c,d]indol-5-one
- a heterogeneous mixture of 4-amino-1,3,4,5-tetrahydro-1-(p-tolylsulphonyllbenz[c,d]indol-5-one hydrochloride (10 gm) and acetic anhydride (100 ml) is heated on a steam bath until homogeneity is achieved (15 minutes).
- the reaction mixture is poured with stirring into water (650 ml).
- the solid is filtered and dried in a steam oven to yield 9.5 gm of 4-acetamino-1,3,4,5-tetrahydro-1-(p-tolylsulphonyl)benz[c,d]indol-5-one, m.p. 180-185°.
- Step 8 4-Acetamino-1,3,4,5-tetrahydro-1-(p-tolylsulphonyl)benz[c,d]indol-5-one(2,3-propylenedithioacetal)
- Step C 4-Acetamino-1,3,4,5-tetrahydro-1-(p-tolylsulphonyl)benz[c,d]indole
- Step D 4-N-Ethylamino-1,3,4,5-tetrahydrobenz[c,d]indole
- the compound (ii) may be converted to the corresponding compound where the group in the 8- position is OH by suitably cleaving the OCH 3 group by using e.g. trimethylsilyl iodide [see J. Org. Chem. 42, 3761 ⁇ 3764 (1977)].
- Halogenation of the tetrahydrobenzindole moiety in the 2-position can be carried out using the process described in von F. Troxler in Helv. Clinc. Acta 40, 2160 (1957).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT80107188T ATE9690T1 (de) | 1979-11-23 | 1980-11-19 | Amino-substituierte tetrahydrobenzindole, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/096,948 US4282240A (en) | 1979-11-23 | 1979-11-23 | Amino substituted tetrahydrobenzindoles |
US96948 | 1979-11-23 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0029581A2 EP0029581A2 (en) | 1981-06-03 |
EP0029581A3 EP0029581A3 (en) | 1981-09-02 |
EP0029581B1 true EP0029581B1 (en) | 1984-10-03 |
Family
ID=22259890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP80107188A Expired EP0029581B1 (en) | 1979-11-23 | 1980-11-19 | Amino substituted tetrahydrobenzindoles, a process for preparing and a pharmaceutical composition containing the same |
Country Status (9)
Country | Link |
---|---|
US (1) | US4282240A (pt) |
EP (1) | EP0029581B1 (pt) |
JP (1) | JPS5687562A (pt) |
AT (1) | ATE9690T1 (pt) |
DE (1) | DE3069381D1 (pt) |
DK (1) | DK497680A (pt) |
ES (1) | ES8203343A1 (pt) |
GR (1) | GR72131B (pt) |
PT (1) | PT72088B (pt) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0148440A1 (de) * | 1983-12-23 | 1985-07-17 | Troponwerke GmbH & Co. KG | 1,3,4,5-Tetrahydrobenz[c,d]indole, ein Verfahren zu ihrer Herstellung und ihre Verwendung |
EP0153083A2 (en) * | 1984-02-06 | 1985-08-28 | Eli Lilly And Company | 6-Substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
EP0162695A1 (en) * | 1984-05-24 | 1985-11-27 | Smithkline Beecham Corporation | 6-Oxygenated-1,3,,4,5-Tetrahydrobenz(cd)indol-4-amines |
EP0332968A1 (de) * | 1988-03-18 | 1989-09-20 | Bayer Ag | 1,3,4,5-Tetrahydrobenz[c,d]indole |
US5204340A (en) * | 1989-04-11 | 1993-04-20 | Eli Lilly And Company | Tetrahydrobenz(c,d)indole serotonin agonists |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU560459B2 (en) * | 1982-06-01 | 1987-04-09 | Abbott Laboratories | Tetrahydro-benzo(e) isoindolines |
US4576959A (en) * | 1984-02-06 | 1986-03-18 | Eli Lilly And Company | 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles |
US4983622A (en) * | 1984-02-06 | 1991-01-08 | Eli Lilly And Company | 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
US5026869A (en) * | 1984-02-06 | 1991-06-25 | Eli Lilly And Company | 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
US5302612A (en) * | 1990-02-26 | 1994-04-12 | Eli Lilly And Company | 6-substituted-hexahydrobenz[cd]indoles |
US5229409A (en) * | 1990-08-15 | 1993-07-20 | Eli Lilly And Company | 6-substituted-tetrahydrobenz[cd]indoles |
US5364856A (en) * | 1991-03-28 | 1994-11-15 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles |
US5244912A (en) * | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3200130A (en) * | 1963-08-27 | 1965-08-10 | Upjohn Co | Derivatives of 1, 3, 4, 5-tetrahydro-benz[cd]indoles |
US4110339A (en) * | 1977-11-25 | 1978-08-29 | Eli Lilly And Company | 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole |
-
1979
- 1979-11-23 US US06/096,948 patent/US4282240A/en not_active Expired - Lifetime
-
1980
- 1980-11-19 DE DE8080107188T patent/DE3069381D1/de not_active Expired
- 1980-11-19 AT AT80107188T patent/ATE9690T1/de not_active IP Right Cessation
- 1980-11-19 EP EP80107188A patent/EP0029581B1/en not_active Expired
- 1980-11-20 GR GR63410A patent/GR72131B/el unknown
- 1980-11-21 DK DK497680A patent/DK497680A/da not_active Application Discontinuation
- 1980-11-21 ES ES497063A patent/ES8203343A1/es not_active Expired
- 1980-11-21 PT PT72088A patent/PT72088B/pt unknown
- 1980-11-25 JP JP16476980A patent/JPS5687562A/ja active Granted
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0148440A1 (de) * | 1983-12-23 | 1985-07-17 | Troponwerke GmbH & Co. KG | 1,3,4,5-Tetrahydrobenz[c,d]indole, ein Verfahren zu ihrer Herstellung und ihre Verwendung |
EP0153083A2 (en) * | 1984-02-06 | 1985-08-28 | Eli Lilly And Company | 6-Substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
EP0153083A3 (en) * | 1984-02-06 | 1987-01-14 | Eli Lilly And Company | 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles |
EP0162695A1 (en) * | 1984-05-24 | 1985-11-27 | Smithkline Beecham Corporation | 6-Oxygenated-1,3,,4,5-Tetrahydrobenz(cd)indol-4-amines |
EP0332968A1 (de) * | 1988-03-18 | 1989-09-20 | Bayer Ag | 1,3,4,5-Tetrahydrobenz[c,d]indole |
US5021438A (en) * | 1988-03-18 | 1991-06-04 | Bayer Aktiengesellschaft | 1,3,4,5-tetrahydrobenz(c,d)indoles |
US5204340A (en) * | 1989-04-11 | 1993-04-20 | Eli Lilly And Company | Tetrahydrobenz(c,d)indole serotonin agonists |
US5462962A (en) * | 1989-04-11 | 1995-10-31 | Eli Lilly And Company | Tetrahydrobenz[c,d]indole serotonin agonists |
Also Published As
Publication number | Publication date |
---|---|
PT72088B (en) | 1982-09-01 |
JPH0139425B2 (pt) | 1989-08-21 |
GR72131B (pt) | 1983-09-19 |
JPS5687562A (en) | 1981-07-16 |
DK497680A (da) | 1981-05-24 |
ATE9690T1 (de) | 1984-10-15 |
DE3069381D1 (en) | 1984-11-08 |
EP0029581A2 (en) | 1981-06-03 |
EP0029581A3 (en) | 1981-09-02 |
ES497063A0 (es) | 1982-04-01 |
PT72088A (en) | 1980-12-01 |
ES8203343A1 (es) | 1982-04-01 |
US4282240A (en) | 1981-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3108483B2 (ja) | インドール誘導体およびこれを有効成分とする抗潰瘍薬 | |
EP0252713B1 (en) | Indolinone derivatives | |
EP0029581B1 (en) | Amino substituted tetrahydrobenzindoles, a process for preparing and a pharmaceutical composition containing the same | |
JP3148253B2 (ja) | ベンゾフリル誘導体類及びそれらの用途 | |
US4564613A (en) | Pyridoindole derivatives, compositions and use | |
EP0198456B1 (en) | 1,7-naphthyridine derivatives and medicinal preparations containing same | |
EP0167901B1 (en) | Active compounds | |
JPS60258162A (ja) | 6‐酸素化‐1,3,4,5‐テトラヒドロベンズ[cd]インドール‐4‐アミン | |
EP0033767B1 (en) | Indolobenzoxazines, processes for preparing and pharmaceutical compositions containing the same | |
JP3037991B2 (ja) | 新規なアコニチン系化合物および鎮痛・抗炎症剤 | |
US4501900A (en) | Amino substituted tetrahydrobenzindoles | |
JP2726999B2 (ja) | イミダゾ[2,1−b]ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤 | |
US4163055A (en) | 2,9-Dioxatricyclo[4,3,1,03,7 ] decane derivatives and pharmaceutical compositions thereof | |
EP0233413A2 (en) | 3-(2-Aminoethyl)indole and -indoline derivatives, processes for their preparation and pharmaceutical compositions containing them | |
US5064852A (en) | Indolinone derivatives | |
US4235903A (en) | 1-Hydroxyalkanamine tetrahydrocarbazoles and cyclopent[b]indoles, compositions and method of use | |
US4482714A (en) | Pyrazino[2',3'-3,4]pyrido[1,2-a]indole derivatives | |
US4777181A (en) | Alpha-2-antagonistic substituted 4-fluoro-isoindolines | |
SE453293B (sv) | 3,3-dialkyl- och 3,3-alkylen-indolinderivat, sett att framstella dessa och farmaceutiska kompositioner innehallande desamma | |
US4515949A (en) | [2-(1H-indol-1-yl)ethyl]-2-piperazine and pyrido[1,2-a]indol-9-one as intermediates for pyrazino(2,3-3,4)pyrido(1,2-a) indoles which are useful for treating hypertension in mammals | |
JPS62425A (ja) | 医薬組成物 | |
KR890002428B1 (ko) | 디엔 유도체의 제법 | |
US4319029A (en) | Hydroxyalkanamide tetrahydrocarbazoles | |
JPH05310749A (ja) | アザビシクロ誘導体 | |
JPH024791A (ja) | ピラノベンゾトリアゾール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
ITCL | It: translation for ep claims filed |
Representative=s name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
17P | Request for examination filed |
Effective date: 19820302 |
|
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 9690 Country of ref document: AT Date of ref document: 19841015 Kind code of ref document: T |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19841010 Year of fee payment: 5 |
|
REF | Corresponds to: |
Ref document number: 3069381 Country of ref document: DE Date of ref document: 19841108 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19841130 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19841231 Year of fee payment: 5 Ref country code: BE Payment date: 19841231 Year of fee payment: 5 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19851119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19851120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19851130 |
|
BERE | Be: lapsed |
Owner name: MERCK & CO. INC. Effective date: 19851130 |
|
ITTA | It: last paid annual fee | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19920917 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19920924 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19921001 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19921126 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19921130 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19931119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19931130 Ref country code: CH Effective date: 19931130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19940601 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19931119 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19940729 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19940802 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
EUG | Se: european patent has lapsed |
Ref document number: 80107188.7 Effective date: 19860805 |